Boston Scientific Corp. racked up a two-fer from the U.S. FDA with approval of its navigation-enabled Farawave Nav ablation catheter and 510(k) clearance for the Faraview software for use with its ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
Fintel on MSN8h
Leerink Partners Upgrades Gilead Sciences (GILD)Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback